CNS Lymphoma: [90Y]Y-PentixaTher Therapy

We are studying the safety and effectiveness of [90Y]Y-PentixaTher in patients with recurrent or refractory central nervous system lymphoma. This trial aims to find the best dose and understand how the treatment works in the body.

Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInjectionNeurologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Gallium (68ga) Chloride
Gallium-68 chloride is a radioactive tracer used in PET scans to help visualize tumors, infections, and other abnormal tissues.
L-Arginine Hydrochloride
L-Arginine hydrochloride is a salt form of the amino acid L-arginine used to support blood vessel health and improve blood flow.
L-Lysine Hydrochloride
L-lysine hydrochloride is an essential amino acid supplement used to support protein building, tissue repair, and prevent lysine deficiency.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Lysakare
PentixaFor
Pentixather

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Universitaetsklinikum Essen AöR
Hematology
Essen, Germany
Klinikum rechts der Isar der TU Muenchen AöR
Department of Nuclear Medicine
Munich, Germany
Sponsor: Pentixapharm AG
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.